Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultrarare genetic diseases. Their therapies and pipeline include biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Approved products are Crysvita for X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO), Mepsevii for mucopolysaccharidosis VII (MPSVII), Dojolvi for long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza for homozygous familial hypercholesterolemia (HoFH). Clinical candidates include DTX401 for glycogen storage disease type Ia, DTX301, and UX701. We show 48 historical shares outstanding datapoints in our coverage of RARE's shares outstanding history.
Understanding the changing numbers of RARE shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like RARE versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching RARE by allowing them to research RARE shares outstanding history
as well as any other stock in our coverage universe. |
Free RARE Email Alerts:
Video: Shares Outstanding Importance
